RNA Atrium Therapeutics, Inc.
USHealthcareAs of 2026-07-09 16:00
Why RNA matters now
Atrium Therapeutics, Inc. (RNA) is a US stock in Healthcare. The latest InvestLog snapshot shows $12.91 with -3.44% on the session and $220.8M in market capitalization; recent performance reads 1-month -2.24% and YTD -14.17%.
The latest financial table shown here is Q1 2026, with revenue of $19.6M, net income of $-16.6M, and EPS of $-0.97. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -24.6%.
The latest indexable market news headline is "Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $25.00. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.93
P/S
10.57
EV/EBITDA
0.75
DCF Value
$-10.11
FCF Yield
-24.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
99.3%
Operating Margin
-318.7%
Net Margin
-315.7%
ROE
-29.7%
ROA
-22.1%
ROIC
-23.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $19.6M | $-16.6M | $-0.97 |
| Q4 2025 | $859.0K | $-48.1M | $-1.70 |
| FY 2025 | $18.6M | $-76.7M | $-4.48 |
| Q3 2025 | $12.5M | $-174.4M | $-1.27 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$25.00
Target (Median)
$25.00
Target Range
$25.00 - $25.00
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.42
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.